跳至主要内容
临床试验/NCT05325398
NCT05325398已完成不适用

Effect of Molecular Hydrogen in Patients With Non Alcoholic Faty Liver Disease

Comenius University1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2020年5月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
30
试验地点
1
主要终点
Changes in blood parameters Coenzyme Q 10 in plasma

研究概览

简要总结

Molecular hydrogen H2 acts as antioxidant which selectively reduces cytotoxic harmful reactive oxygen species ROS and concomitantly acts as biological messenger, which mediates several signaling pathways that play cytoprotective role in many human diseases. Due to their small size and high permeability, H2 is easily transportable into subcellular structures as mitochondria.

详细描述

Non-alcoholic fatty liver disease, NAFLD, is the most common cause of liver disease. According to the forecasts, the non-alcoholic steatohepatitis will be the most common cause of liver transplantation and hepatic mortality in 2030. NAFLD is also a significant risk factor for the development of hepatocellular carcinoma, even in the non-cirrhotic stage of liver disease. The prevention of the progression of NAFLD to NASH (nonalcoholic steatohepatitis) is therefore a key factor in preventing this unfavorable prognosis.

Obesity and its associated comorbidities are among the most widespread and challenging conditions in the confrontation of the medical profession in the 21st century. The main metabolic consequence of obesity is insulin resistance, which is strongly associated with the storage of triacylglycerols in the liver. Hepatic steatosis may be associated with steatohepatitis, a condition that can lead to liver cirrhosis and, in the final stage, liver transplantation.

According to various sources, the incidence of NAFLD in the population is 20-30%, in obese up to 60%, which makes it the most common liver disease. In the USA, it is even 3 times more common than type 2 diabetes mellitus and 5-10 times more common than chronic hepatitis C. The incidence of non-alcoholic steatohepatitis NASH is 2-3% and is now thought to be the cause of up to 80% cryptogenic liver cirrhosis. The risk of developing cirrhosis in patients with simple hepatic steatosis is 1-2% over 8 years.

Insulin resistance, which is defined as an elevated HOMA (homeostasis model assessment) index above 1,4, is found in 70% of patients with NAFLD and plays a major role in the accumulation of triacylglycerols TAG (triacylglyceride) in the liver. Through the rise of hormone-sensitive lipase, hyperinsulinemia leads to the hydrolysis of free fatty acids FFA from visceral adipocytes to the portal vein, through which they enter directly into the liver, where they are esterified to TAG. Reducing the production of apolipoprotein B-100, which is an important part of their secretion from the liver into the circulation in the form of VLDL-lipoproteins, is also a potentiating factor in TAG deposition in the liver. Free oxygen radicals ROS (reactive oxygen species), which are formed due to the oxidative stress, are formed directly in the hepatocyte. However, their formation in visceral adipocytes has also been shown to be involved in liver damage. The main site of ROS are mitochondria. In NAFLD, known mitochondrial dysfunction leads to pathological oxidation of FFA (free fatty acid) in peroxisomes and microsomes, making them another source of ROS. ROS, through damage of the mitochondrial membrane by lipoperoxidation and induction of Fas-ligand expression on the hepatocyte, leads to cell apoptosis.

By activating stellate cells, a larger amount of extracellular matrix is formed - Mallory's hyaline, which is associated with the formation of balloon degeneration of hepatocytes, that is a typical histological feature of NASH.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
33 Years 至 69 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •People with age 33-69 years
  • •Confirmation of fatty liver by ultrasonographic examination
  • •Signed informed consent
  • •Alcohol intake according to the AUDIT questionnaire 5 or less points for men or 4 or less points for women

排除标准

  • •Unsigned informed consent
  • •BMI < 25
  • •Presence of severe inflammatory disease with activity (Crohn's disease, ulcerative colitis, active tuberculosis, rheumatoid arthritis, etc.)
  • •Presence of acute infectious disease (acute hepatitis, peritonitis, cholecystitis, pancreatitis, etc.)
  • •Presence of active neoplastic disease
  • •Alcohol intake according to the AUDIT questionnaire more as 5 points for men or more as 4 points for women

研究组 & 干预措施

probands in the control group

Placebo Comparator

13 probands in the control group who will receive placebo.

干预措施: placebo (Dietary Supplement)

patients with NAFLD

Active Comparator

17 patients will receive molecular hydrogen

干预措施: HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada (Dietary Supplement)

结局指标

主要结局

Changes in blood parameters Coenzyme Q 10 in plasma

时间窗: 8 weeks

Coenzyme Q 10 in plasma (μmol/L)

Changes in blood parameters Insulin

时间窗: 8 weeks

Insulin (mIU/L)

Changes in blood parameters Beta carotene

时间窗: 8 weeks

Beta carotene (μmol/L)

Changes in blood parameters Coenzyme Q 10 in platelets

时间窗: 8 weeks

Coenzyme Q 10 in platelets (pmol/10\^9 cells)

Changes in blood parameters ALT

时间窗: 8 weeks

ALT (alaninaminotransferase) ukat/L

Changes in blood parameters Glucose

时间窗: 8 weeks

Glucose (mmol/L)

Changes in blood parameters Cholinesterase

时间窗: 8 weeks

Cholinesterase (ukat/L)

Changes in blood parameters TBARS

时间窗: 8 weeks

TBARS (μmol/L)

Changes in blood parameters AST

时间窗: 8 weeks

AST (aspartataminotransferase) ukat/L

Changes in blood parameters GMT

时间窗: 8 weeks

GMT (gamaglutamyltransferase) ukat/L

Changes in blood parameters Cholesterol

时间窗: 8 weeks

Cholesterol (mmol/L)

Changes in blood parameters Triacylglycerol

时间窗: 8 weeks

Triacylglycerol (mmol/L)

Changes in blood parameters Hemoglobin

时间窗: 8 weeks

Hemoglobin (g/L)

Changes in blood parameters LDH

时间窗: 8 weeks

LDH (lactatdehydrogenase) (mU/mL)

Changes in blood parameters MMP-9

时间窗: 8 weeks

MMP-9 (matrix-metalloproteinase 9) (% of change)

Changes in blood parameters SOD

时间窗: 8 weeks

SOD (superoxiddismutase) (ng/mL)

Changes in blood parameters NFkB

时间窗: 8 weeks

NFkB (nuclear factor kappa B) (% of change)

Changes in blood parameters Alpha tocopherol

时间窗: 8 weeks

Alpha tocopherol (μmol/L)

Changes in body parameters: Weight in kilograms, height in meters, waist circumference in centimeters

时间窗: 8 weeks

The following parameters will be measured for each proband before (time 0) and after the study (time 8 weeks): a) weight and height will be combined to report BMI in kg/m\^2, waist circumference in cm.

Changes in blood parameters ALP

时间窗: 8 weeks

ALP (alkaline phosphatase) ukat/L

Changes in blood parameters Albumin

时间窗: 8 weeks

Albumin (g/L)

Changes in blood parameters Bilirubin

时间窗: 8 weeks

Bilirubin total (umol/L)

Changes in blood parameters HOMA index

时间窗: 8 weeks

HOMA index (calculation)

Changes in blood parameters Leucocytes

时间窗: 8 weeks

Leucocytes (x10\^9/L)

Changes in blood parameters MDA

时间窗: 8 weeks

MDA (malondialdehyde) (μmol/L)

Changes in blood parameters 8-OHdG

时间窗: 8 weeks

8-OHdG (8-hydroxy-2-deoxyguanosine) (ng/mL)

Changes in blood parameters TNF alfa

时间窗: 8 weeks

TNF alfa (tumor necrosis factor alpha) (% of change)

Changes in blood parameters HSP 60

时间窗: 8 weeks

HSP 60 (heat shock protein 60) (% of change)

Changes in blood parameters HSP 70

时间窗: 8 weeks

HSP 70 (heat shock protein 70) (% of change)

Changes in blood parameters Platelets

时间窗: 8 weeks

Platelets (x10\^9/L)

Changes in blood parameters MMP-2

时间窗: 8 weeks

MMP-2 (matrix metalloproteinase2) (% of change)

Changes in blood parameters Gama tocopherol

时间窗: 8 weeks

Gama tocopherol (μmol/L)

Changes in blood parameters Coenzyme Q 10 in whole blood

时间窗: 8 weeks

Coenzyme Q 10 in whole blood (μmol/L)

次要结局

未报告次要终点

研究者

发起方
Comenius University
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验